MedTrace Logo

A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma

NCT07799220 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-09-02

No results posted yet for this study

Summary

The researchers are doing this study to find out whether the combination of zanubrutinib, obinutuzumab, and sonrotoclax (BOSon) is an effective treatment approach for people with mantle cell lymphoma (MCL).

Conditions

Interventions

DRUG

Zanubrutinib

PO twice daily of each 28-day cycle

DRUG

Obinutuzumab

IVPB on days 1, 8, and 15 of cycle 1; and IVPB on day 1 of cycles 2-8

DRUG

Sonrotoclax

Sonrotoclax will be initiated on C2D1 using the ramp-up schedule

Sponsors & Collaborators

Principal Investigators

  • Zachary Epstein-Peterson, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-09-30
Completion
2028-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07799220 on ClinicalTrials.gov